Reuters logo
BRIEF-Pharma Mar completes patient recruitment for phase III trial with PM1183 for ovarian cancer
October 18, 2016 / 6:36 AM / a year ago

BRIEF-Pharma Mar completes patient recruitment for phase III trial with PM1183 for ovarian cancer

Oct 18 (Reuters) - Pharma Mar SA :

* Completes patient recruitment for phase III trial with lurbinectedin (PM1183), CORAIL, for the treatment of platinum resistant ovarian cancer Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below